Emergent BioSolutions Inc. (NYSE: EBS) has secured a $50 million contract option from the Biomedical Advanced Research and Development Authority (BARDA) to procure doses of Cyfendus® (Anthrax Vaccine Adsorbed, Adjuvanted). This award follows a previous contract modification of $30.0 million to supply the same vaccine earlier this year.
Cyfendus® vaccine, which was approved by the U.S. Food & Drug Administration (FDA) in July 2023, is indicated for post-exposure prophylaxis of anthrax disease following suspected or confirmed exposure to Bacillus anthracis in individuals 18 through 65 years of age when given with recommended antibacterial drugs.
In addition to the Cyfendus® vaccine, Emergent's anthrax franchise includes the BioThrax® vaccine, Anthrasil® (Anthrax Immune Globulin Intravenous (Human)), and Raxibacumab. The project has been supported in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority under contract HHSO100201600030C.
The company's Senior Vice President, Paul Williams, emphasized the significant public health threat posed by anthrax and the importance of bolstering anthrax preparedness. He noted that this procurement award further demonstrates Emergent's commitment to public health preparedness.
The press release also provides important safety information for Cyfendus® vaccine, including contraindications, allergic reactions, altered immunocompetence, and potential adverse reactions.
Following these announcements, the company's shares moved -1.8%, and are now trading at a price of $10.09. For more information, read the company's full 8-K submission here.
